CoChat

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Open access
DeAngelo, Daniel J., Stock, Wendy, Stein, Anthony S., Shustov, Andrei, Liedtke, Michaela, Schiffer, Charles A., Vandendries, Erik, Liau, Katherine, Ananthakrishnan, Revathi, Boni, Joseph, Laird, A. Douglas, Fostvedt, Luke, Kantarjian, Hagop M., Advani, Anjali S. · 2017 · Blood Advances
Cited by 135

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Key Points: Weekly InO 1.8 mg/m2 per cycle is associated with manageable toxicities and encouraging activity in patients with relapsed/refractory ALL. Achievement of MRD negativity and disease burden was not correlated; InO may thus be effective regardless of baseline disease severity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2016001925

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 135

Metadata

Authors
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., Vandendries, E., Liau, K., Ananthakrishnan, R., Boni, J., Laird, A. D., Fostvedt, L., Kantarjian, H. M., & Advani, A. S.
Venue
Blood Advances
Published
2017-06-27
Volume
1
Issue
15
Pages
1167-1180
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2725721905
Cited by
135
References
4
FWCI
17.91
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. https://app.cochat.ai/papers/10.1182/bloodadvances.2016001925
The paper
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., Vandendries, E., Liau, K., Ananthakrishnan, R., Boni, J., Laird, A. D., Fostvedt, L., Kantarjian, H. M., & Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances. https://doi.org/10.1182/bloodadvances.2016001925

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.